Login to Your Account



Basilea Stock Takes a Hit on FDA Guidelines for Antibiotic Trials

By Catherine Shaffer
Staff Writer

Friday, August 23, 2013
The FDA has maintained a firm stance on clinical trial requirements for Basilea Pharmaceutica Ltd.'s broad-spectrum antibiotic ceftobiprole for skin infections. In its half-year financial update, Basilea indicated that the agency would require two pivotal trials per indication. Basilea's stock (SW:BSLN) closed Thursday at CHF70.75 (US$76.67), down CHF2.45.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription